Under the terms of the agreement, APT employees will remain employed at the site, and the plant will continue to manufacture certain Astellas pharmaceutical products on a contract basis.
Astellas will continue to source a stable supply of high-quality products from the facility under the oversight of Avara following the acquisition.
"We are excited to have the APT organization join the Avara team and to add this significant capability to the Avara Company," said Tim Tyson, Chairman and CEO of Avara.
Tyson added, "We are honored to have the strategic partnership with Astellas and to manufacture key products for them. We are excited to be able to transition this Astellas center of technical excellence to a worldwide pharmaceutical services center of excellence."